Brokerages expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to announce earnings of $0.93 per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for IDEXX Laboratories’ earnings, with estimates ranging from $0.89 to $0.99. IDEXX Laboratories reported earnings per share of $0.65 in the same quarter last year, which would indicate a positive year over year growth rate of 43.1%. The business is expected to report its next quarterly earnings results on Friday, April 27th.
On average, analysts expect that IDEXX Laboratories will report full year earnings of $3.89 per share for the current financial year, with EPS estimates ranging from $3.55 to $4.21. For the next fiscal year, analysts expect that the business will post earnings of $4.75 per share, with EPS estimates ranging from $4.23 to $5.03. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The company had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. During the same quarter in the prior year, the business earned $0.58 earnings per share. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis.
Several equities research analysts recently issued reports on the company. Bank of America boosted their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday. Piper Jaffray Companies boosted their price target on IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research note on Thursday. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price target on shares of IDEXX Laboratories in a research note on Monday, January 29th. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories presently has a consensus rating of “Buy” and a consensus price target of $189.71.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at $179,910,017.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total value of $2,972,700.00. Following the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at $177,885,046.80. The disclosure for this sale can be found here. Insiders have sold 112,160 shares of company stock valued at $17,252,185 over the last 90 days. Corporate insiders own 2.77% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Koch Industries Inc. lifted its stake in IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after purchasing an additional 1,396,113 shares during the last quarter. Janus Henderson Group PLC lifted its stake in IDEXX Laboratories by 486.4% during the second quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock worth $182,711,000 after purchasing an additional 938,888 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in IDEXX Laboratories by 30.1% during the third quarter. Bank of New York Mellon Corp now owns 955,225 shares of the company’s stock worth $148,527,000 after purchasing an additional 220,818 shares during the last quarter. American Century Companies Inc. lifted its stake in IDEXX Laboratories by 32.3% during the fourth quarter. American Century Companies Inc. now owns 946,391 shares of the company’s stock worth $147,997,000 after purchasing an additional 231,216 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. lifted its stake in IDEXX Laboratories by 60.1% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 830,379 shares of the company’s stock worth $129,115,000 after purchasing an additional 311,712 shares during the last quarter. Hedge funds and other institutional investors own 86.72% of the company’s stock.
Shares of IDEXX Laboratories (IDXX) opened at $185.58 on Monday. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. The stock has a market capitalization of $16,254.08, a P/E ratio of 63.39, a P/E/G ratio of 1.89 and a beta of 0.58. IDEXX Laboratories has a 12 month low of $140.21 and a 12 month high of $198.73.
ILLEGAL ACTIVITY NOTICE: This story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thestockobserver.com/2018/02/05/zacks-brokerages-anticipate-idexx-laboratories-inc-idxx-to-announce-0-93-earnings-per-share.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.